Core Viewpoint - Inventiva reported preliminary unaudited financial results for the full year ending December 31, 2025, highlighting significant changes in cash flow, revenues, and operational expenses as it continues to focus on developing therapies for metabolic dysfunction-associated steatohepatitis (MASH) [1]. Financial Position - As of December 31, 2025, the company's cash and cash equivalents were €99.3 million, with short-term deposits amounting to €131.6 million, an increase from €96.6 million in cash and cash equivalents in 2024 [2]. - The company estimates that its cash resources will support operations until the middle of the first quarter of 2027, potentially extending to the middle of the third quarter of 2027 with additional proceeds from the exercise of warrants [7]. Cash Flow Analysis - Net cash used in operating activities was (€104.6) million in 2025, a 22% increase from (€85.9) million in 2024, primarily due to a strategic pipeline prioritization plan and lower revenues from licensing agreements [3]. - Net cash used in investing activities was (€133.2) million in 2025, significantly higher than €8.7 million generated in 2024, mainly due to new short-term deposits [4]. - Net cash generated from financing activities was €241.1 million in 2025, up from €145.6 million in 2024, driven by proceeds from structured financing and a public offering in the United States [5]. Revenue Performance - The company's revenues for 2025 were €4.5 million, a decrease from €9.2 million in 2024, primarily consisting of milestone payments and credit notes from licensing agreements [8]. Future Financial Reporting - The company plans to publish its audited financial results for the full fiscal year 2025 on March 30, 2026, after the U.S. market close [9]. Company Overview - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral therapies for MASH, currently evaluating lanifibranor in a pivotal Phase 3 clinical trial [10].

Summary of Inventiva's Conference Call Company Overview - **Company**: Inventiva (NasdaqGM:IVA) - **Event**: 2026 Conference at Guggenheim's Emerging Outlook Biotech Conference - **Key Speaker**: CEO Andrew Obenshain Industry Context - **Industry**: MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease) - **Market Potential**: The MASH market is evolving with recent clinical successes, including two approvals and a billion-dollar market potential for F2 and F3 patients. The diagnosis rate is increasing, with over 15 million patients in the U.S. and 375,000 addressable patients in F2 and F3 categories [2][10]. Core Points and Arguments - **Clinical Trials**: Inventiva is preparing for a Phase 3 trial readout for lanifibranor, a pan-PPAR agonist targeting F2 and F3 patients. The trial is fully enrolled, and data cleaning is underway [3][8]. - **Market Positioning**: Lanifibranor is expected to be used alongside GLP-1 treatments, with a significant effect size of 18% after 6 months compared to 12% for Rezdiffra after 12 months [11][12]. - **Patient Demographics**: The patient population is split between non-diabetics (40%) and diabetics (60%). Lanifibranor is particularly beneficial for diabetic patients due to its ability to reduce HbA1c levels [10][12]. - **Trial Design**: The NATiV3 study is designed conservatively, allowing for a dropout rate of up to 30%, with current rates below this threshold [13][14]. The trial includes a randomized design with a focus on both fibrosis and steatosis improvement [16][18]. - **Safety and Tolerability**: Lanifibranor is a novel chemical entity designed to mitigate historical safety concerns associated with PPARs. Weight gain is a potential side effect, but 50% of patients experience no weight gain, and 20% have modest gains [30][32]. Additional Important Insights - **Strategic Partnerships**: There is a cautious sentiment in the pharmaceutical industry regarding PPARs due to past experiences. However, positive Phase 3 data could overcome these concerns [41]. - **Future Trials**: Inventiva plans to conduct an F4 outcomes trial with lanifibranor, focusing on patients with portal hypertension [42][43]. - **Cash Runway**: The company has structured its finances to support operations through Q3 2027, with a potential third tranche of funding of EUR 118 million contingent on positive trial data [55]. Conclusion Inventiva is positioned to make significant strides in the MASH market with lanifibranor, backed by a strong clinical trial framework and a clear understanding of market dynamics. The upcoming Phase 3 data will be crucial for the company's future and potential partnerships.

Market Overview - The S&P 500 and Nasdaq Composite declined by 0.1% and 1.9% respectively, while the Dow Jones Industrial Average increased by 2.5% last week, indicating a mixed performance across major indexes [1] - The divergence in market performance was attributed to a rotation in investor preferences rather than overall market weakness, with rising Treasury yields making high-valuation growth stocks less appealing [1] Sector Performance - Optimism regarding economic resilience led to increased buying in cyclically sensitive and defensive sectors, with industrials benefiting from infrastructure and manufacturing strength, financials gaining from higher yields, and energy rising with firmer oil prices [2] - This shift underscores a focus on earnings stability and tangible cash flows among investors [2] Zacks Research Performance - Kennametal Inc. (KMT) shares surged by 44.8% since being upgraded to a Zacks Rank 1 (Strong Buy) on December 8, outperforming the S&P 500's 0.7% increase [3] - Inventiva S.A. (IVA) also saw a return of 42.4% since its upgrade to Zacks Rank 1 on the same date [4] - An equal-weight portfolio of Zacks Rank 1 stocks outperformed the equal-weight S&P 500 index by 7 percentage points, returning 17.81% compared to 10.85% for the index [4] Zacks Recommendations - Clearway Energy, Inc. (CWENA) and Pursuit Attractions and Hospitality, Inc. (PRSU) saw share increases of 16.7% and 5.4% respectively since their upgrades to Outperform on December 10 and December 11 [6] - The Zacks Recommendation system aims to predict stock performance over the next 6 to 12 months, based on trends in earnings estimate revisions [7] Focus List and Portfolios - Celanese Corporation (CE) gained 32.9% over the past 12 weeks since being added to the Zacks Focus List, while Intellia Therapeutics, Inc. (NTLA) returned 29% over the same period [9] - The Zacks Focus List portfolio returned 22.1% in 2025, outperforming the S&P 500 index's 17.9% gain [10] - The Earnings Certain Admiral Portfolio (ECAP) returned -1.67% for 2025, underperforming the S&P 500 index's 17.9% gain, but had a return of 16.26% in 2024 compared to the S&P 500's 24.89% [14] Dividend Portfolio Performance - Illinois Tool Works Inc. (ITW) and Fastenal Company (FAST) returned 19.6% and 16.8% respectively over the past 12 weeks, benefiting from investor interest in quality dividend stocks amid market volatility [16] - The Earnings Certain Dividend Portfolio (ECDP) returned -0.6% for 2025, underperforming the Dividend Aristocrat ETF's 6.8% gain [17] Top 10 Stocks Performance - Monolithic Power Systems (MPWR) increased by 31.4% since January 5, 2026, compared to the S&P 500 Index's 1.1% increase [20] - The Top 10 portfolio has produced a cumulative return of 2,472.7% since 2012, significantly outperforming the S&P 500 index's 561.6% return [21]

Core Insights - Inventiva, a clinical-stage biopharmaceutical company, focuses on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) [1][2] - CEO Andrew Obenshain will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026, in New York City [1][2] Company Overview - Inventiva is engaged in the research and development of oral small molecule therapies targeting MASH and other diseases with significant unmet medical needs [2] - The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for adult patients with MASH [2] Stock Information - Inventiva is publicly listed on Euronext Paris (ticker: IVA) and the Nasdaq Global Market in the United States (ticker: IVA) [3]

Core Insights - A significant increase in Inventiva shares, approximately 50% in the initial weeks of 2026, indicates strong investor interest in the company despite its current loss-making status [1] Company Summary - Inventiva is a French biotech firm poised to enter a rapidly growing market, attracting attention from investors looking for potential opportunities [1]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Inventiva S.A. Sponsored ADR (IVA) - IVA currently holds a Momentum Style Score of B, indicating strong momentum characteristics [2] - The stock has a Zacks Rank of 2 (Buy), suggesting it is positioned for potential outperformance [3] Performance Metrics - Over the past week, IVA shares increased by 9.83%, while the Zacks Medical - Biomedical and Genetics industry rose by 1.2% [5] - In the last month, IVA's price change was 59.6%, significantly outperforming the industry's 0.68% [5] - Over the past quarter, IVA shares have risen by 66.28%, and by 206.87% over the last year, compared to the S&P 500's increases of 2.92% and 14.29%, respectively [6] Trading Volume - IVA's average 20-day trading volume is 552,066 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the last two months, one earnings estimate for IVA has increased, while none have decreased, raising the consensus estimate from -$1.53 to -$1.25 [9] - For the next fiscal year, one estimate has moved upwards with no downward revisions during the same period [9] Conclusion - Given the strong performance metrics and positive earnings outlook, IVA is recommended as a 2 (Buy) stock with a Momentum Score of B, making it a promising investment opportunity [11]

Company Overview - Inventiva has undergone a significant transformation in the last 18 months, indicating a strategic shift or development within the organization [4] - The company is currently conducting a fully enrolled Phase III trial for its lead asset, lanifibranor, which is positioned as a potential best-in-class oral therapy for MASH [4] Clinical Development - The Phase III trial design is based on a successful Phase IIb trial involving over 200 patients, which was published in the New England Journal of Medicine with positive results [4] - The readout for the Phase III trial is anticipated in the second half of this year, suggesting a critical upcoming milestone for the company [4] Financial Position - The company has received a substantial amount of funding, which may support its ongoing clinical trials and operational activities [5]

Summary of Inventiva's Presentation at JPMorgan Healthcare Conference Company Overview - **Company**: Inventiva - **CEO**: Andrew Openshin - **Lead Asset**: Lanifibranor, an oral therapy for MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease) - **Recent Transformation**: The company has undergone significant changes in the last 18 months, including a fully enrolled phase three trial and substantial funding [2][3] Financial Highlights - **Funding**: - $411 million raised in October 2024 - Additional $172 million raised in October [3] - **Cash Balance**: Expected to last until Q3 2027, assuming positive data from trials [21] Clinical Development - **Phase 3 Trial**: - Fully recruited with over 1,000 patients enrolled - Anticipated readout in the second half of the year - Focus on F2 and F3 patient populations, excluding F1 patients [3][17] - **Phase 2b Results**: - 18% effect size on fibrosis and 24% on MASH resolution - Significant improvements in cardiometabolic markers [11][12] Market Opportunity - **MASH Market Size**: Expected to grow to $15 billion by 2035 - **Current Diagnosis Rate**: Approximately 2 million diagnosed MASH patients in the U.S., representing a 25% increase since 2024 [5][6] - **Target Patient Population**: F2 and F3 patients, approximately 375,000 in the U.S. [6] Competitive Landscape - **Treatment Evolution**: - GLP-1 therapies are expected to be the backbone for F1, F2, and F3 patients - Lanifibranor positioned as a complementary oral therapy [7][8] - **Safety Profile**: - Low rates of peripheral edema (2%) and milder weight gain compared to previous PPAR agonists [15][16] Future Plans - **Outcomes Trial**: Planned for patients with compensated cirrhosis MASH to confirm clinical benefits [18] - **Market Launch**: Anticipated for 2028, with strategic preparations ongoing for commercialization in 2026 [20][21] Management and Strategy - **Management Team**: Strengthened with experienced professionals from Intercept and Ipsen [4] - **Strategic Preparation**: Focus on market research and building medical affairs presence in 2026 [24] Additional Insights - **Patient Impact**: Emphasis on the potential to reverse stages of fibrosis and improve patient outcomes [22] - **Company Positioning**: Plans to remain France-based while expanding U.S. commercial infrastructure [23] This summary encapsulates the key points from Inventiva's presentation, highlighting the company's strategic direction, clinical developments, market opportunities, and future plans.

Lanifibranor's Potential - Lanifibranor is presented as a potential best-in-disease oral therapy for MASH (Metabolic dysfunction-Associated SteatoHepatitis), targeting progressive fibrosis in F2/F3 MASH patients[1,5] - The company anticipates regulatory filings in 2027 and a potential commercial launch in 2028, pending approval[8] - Phase 2b trial data showed a 24% effect size on the dual endpoint of fibrosis improvement and MASH resolution in just 24 weeks[70] - The Phase 3 NATiV3 clinical trial is fully recruited with 1,009 patients in the main cohort and 410 in the exploratory cohort[56] - Topline data from the Phase 3 trial is expected in the second half of 2026[8,64] MASH Market and Medical Understanding - The MASH market is expected to exceed $15 billion by 2035[15] - Approximately 19 million were diagnosed with MASH in the U S in 2025, representing ~10% of the patients with MASH[13] - Approximately 910,000 patients have clinically actionable F2/F3 disease, with about 374,000 (~40%) under treated care[14] Financial Position - The company raised $172 million from investors in November 2025[8] - The company's cash runway extends until the middle of Q3 2027, assuming full exercise of the 3rd tranche[8,67]

Core Viewpoint - Shares of Inventiva S.A. (IVA) have increased by 13.8% recently, closing at $5.1, with a mean price target of $15.33 suggesting a potential upside of 200.6% according to Wall Street analysts [1] Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $7.25, indicating variability among analysts; the lowest estimate is $3.00 (41.2% decline), while the highest is $26.00 (409.8% increase) [2] - A low standard deviation signifies strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about IVA's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which correlates with potential stock price increases [11] - Over the past 30 days, the Zacks Consensus Estimate for the current year has risen by 10.2%, with one estimate moving higher and no negative revisions [12] Zacks Rank and Investment Potential - IVA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While consensus price targets may not be entirely reliable, the implied direction of price movement appears to be a useful guide for investors [14]